Last reviewed · How we verify

Elrexfio — Competitive Intelligence Brief

Elrexfio (Elranatamab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Bispecific antibody. Area: Oncology.

marketed Bispecific antibody BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells Oncology Bispecific antibody Live · refreshed every 30 min

Target snapshot

Elrexfio (Elranatamab) — Pfizer. Bispecific antibody binding BCMA on myeloma cells and CD3 on T-cells, causing cytolysis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Elrexfio TARGET Elranatamab Pfizer marketed Bispecific antibody BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells 2023-01-01
Elrexfio elranatamab Pfizer marketed Bispecific antibody BCMA (B-cell maturation antigen) on plasma cells, plasmablasts, and multiple myeloma cells; CD3 on T-cells 2023-01-01
Elrantamab elrantamab Pfizer marketed Bispecific Antibody BCMA (B-cell maturation antigen)
KN046 KN046 Jiangsu Alphamab Biopharmaceuticals Co., Ltd phase 3 Bispecific antibody; PD-L1/4-1BB bispecific immune checkpoint modulator PD-L1 and 4-1BB
BAT1706 BAT1706 Bio-Thera Solutions phase 3 Bispecific antibody; PD-1/TGF-β inhibitor PD-1 and TGF-β
ASKC202+ Limertinib ASKC202+ Limertinib Jiangsu Aosaikang Pharmaceutical Co., Ltd. phase 3 Bispecific antibody + third-generation EGFR tyrosine kinase inhibitor combination EGFR (epidermal growth factor receptor) and c-MET (mesenchymal-epithelial transition factor)
CHS-1420 CHS-1420 Coherus Oncology, Inc. phase 3 Bispecific antibody CD47 and CD40

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Bispecific antibody class)

  1. Shanghai Miracogen Inc. · 3 drugs in this class
  2. Atom Therapeutics Co., Ltd · 2 drugs in this class
  3. Pfizer · 2 drugs in this class
  4. Allergan · 1 drug in this class
  5. AstraZeneca · 1 drug in this class
  6. BioNTech SE · 1 drug in this class
  7. DualityBio Inc. · 1 drug in this class
  8. Coherus Oncology, Inc. · 1 drug in this class
  9. Genmab · 1 drug in this class
  10. Amgen · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Elrexfio — Competitive Intelligence Brief. https://druglandscape.com/ci/elrexfio. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: